Background: Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein with a -3-fold longer tl/2 and greater biological activity compared with recombinant human erythropoietin (rHuEPO).
INTRODUCTION
End-stage renal disease (ESRD) is a serious, life-threatening condition involving a full decline or failure in renal function. According to data from the National Association of Renal Disease Patient Registry, 1 7730 patients in Greece had a diagnosis of ESRD in 1993, and this incidence has increased by 12% each year since. Of the patients with ESRD receiving dialysis, 87% undergo hemodialysis and 13% receive peritoneal dialysis. Only 150 renal transplantations are performed each year in Greece, thus emphasizing the importance of appropriate ambulatory care for patients undergoing dialysis)
It is now well established that erythropoietin is the primary regulator of erythropoiesis and that decreased production of this glycoprotein by the kidney causes the anemia associated with ESRD. [2] [3] [4] Erythropoietin supports the survival, proliferation, and differentiation of erythroid progenitor cells in the bone marrow. Recombinant human erythropoietin (rHuEPO), a glycoprotein with biological and physical characteristics similar to endogenous erythropoietin, has become the standard of care worldwide for the treatment of anemia in patients with ESRD. Therapy with rHuEPO has been proved to increase red blood cell (RBC) mass and reduce the need for RBC transfusion. 5 Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein that works by the same mechanism as endogenous erythropoietin. Darbepoetin alfa has 2 more sialic acid-containing carbohydrate chains compared with rHuEPO. 6-8 Due to its increased carbohydrate content, darbepoetin alfa has a tl/2 -3-fold longer than that of rHuEPO in patients with chronic renal disease. Due to this longer tu2 plus greater biological activity (as measured by hemoglobin [Hb] concentration) compared with rHuEPO, darbepoetin alfa maintains effective control of Hb concentrations with less-frequent dosing compared with rHuEPO. [9] [10] [11] In addition, evidence suggests that IV administration of darbepoetin alfa resuits in greater increases in Hb concentration than SC administration. 12 Furthermore, the IV and SC dose requirements do not differ with darbepoetin alfa, contrary to experience with rHuEPO.
The primary objective of this study was to assess whether unit dosing of darbepoetin alfa (rounding to the nearest prefilled syringe size) would maintain Hb concentrations in the target range of 10 to 13 g/dL, as recommended in the European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure 13 in patients undergoing dialysis and switching from rHuEPO. The mode, dose, and frequency of administration of darbepoetin alfa were also compared with those of baseline rHuEPO. The secondary study objective was to assess the tolerability of long-term (24-week) darbepoetin alfa treatment in this patient population.
PATIENTS AND METHODS
This Phase Illb, 24- week, open-label clinical trial was conducted at 22 centers across Greece as part of a larger European collaborative effort in order to evaluate the efficacy and tolerability of darbepoetin alfa in controlling Hb concentration in patients with ESRD receiving peritoneal dialysis or hemodialysis. The study protocol was approved both by the institutional review board and the ethics committee at each participating clinical site. The research protocol was also evaluated and approved by the National Organisation for Medicines, Athens, Greece, which is the Greek regulatory authority responsible for overseeing clinical trials. Written informed consent was obtained from all patients prior to study initiation, as required by Greek law and suggested by the International Conference on Harmonisation-Good Clinical Practice guidelines. 14
Patient Eligibility
Patients who met all of the following criteria were eligible for participation in the study: age __.18 years; a diagnosis of ESRD; hemodialysis or peritoneal dialysis treatment for at least 6 months before screening; clinical stability; mean of 2 measurements of the Hb concentration between 10 and 13 g/dL at all screening and baseline assessments; stable rHuEPO SC or IV therapy QD, BIW, or TIW for at least 8 weeks before screening (stable was defined as <25% increase or decrease in weekly dosage over 8 weeks); adequate iron stores (serum ferritin concentration, _100 pg/L or transferrin saturation ~20%) during the screening period; availability for follow-up assessments; ability to comprehend the study instructions; and written informed consent for participation in the study.
Patients who fulfilled any of the following criteria were ineligible for participation in the study: treatment for grand mal epilepsy within the past 6 months; congestive heart failure (New York Heart Association class Ill or IV); uncontrolled hypertension (defined as predialysis diastolic blood pressure ___110 mm Hg during the screening period); clinical evidence of current uncontrolled hyperparathyroidism (eg, serum parathyroid hormone concentration >1500 pg/mL within the past 12 months); major surgery within 3 months before screening (excluding vascular access surgery); currently receiving antibiotic treatment for infection; current peritonitis; alanine aminotransferase and aspartate aminotransferase levels >2-fold the upper limit of normal; previously diagnosed HIV or chronic hepatitis B virus infection; clinical evidence of current malignancy (excluding basal cell or squamous cell carcinoma); RBC transfusion within 12 weeks before screening or during the screening/baseline period or active hemorrhage; androgen therapy within 12 weeks before screening; systemic hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy); myeloma; hemolytic anemia; or enrolled in or had not yet completed a period of at least 30 days since ending other investigational device or drug trial(s). Patients receiving other investigational agent(s), such as peritoneal dialysate, could enter the study only after discussion and agreement with the sponsor. Patients were also ineligible if they had a psychiatric, addictive, or other disorder that compromised their ability to give truly informed consent or was likely to alter compliance; if they were pregnant (women of childbearing potential must have been using adequate contraception) or breastfeeding; or if they were anticipating or scheduled for living-donor renal transplantation. Any patient who required the following medications or treatments was withdrawn from the study: RBC transfusion(s) during the screening/ baseline period, rHuEPO therapy, androgen therapy, or any other investigational drugs throughout the study. Figure 1 shows the study design. After an initial 1-week screening period and a 1-week baseline period, patients were switched to darbepoetin alfa. In patients receiving rHuEPO BIW or TIW, the dosing frequency was reduced to QW. In patients receiving rHuEPO QW, dosing frequency was reduced to Q2W. The study drug treatment period was 24 weeks, which included a 20-week drugtitration period and a 4-week stable-dose evaluation period, followed by a 1-week end-of-study period. Due to the tl/2 of circulating RBCs (-60 days in patients with chronic renal disease), it was anticipated that the Hb concentration would reach equilibrium 20 to 24 weeks after switching from rHuEPO to darbepoetin alfa. 15 The starting dose of darbepoetin alfa was determined by the patient's accumulated weekly dose of rHuEPO at the time of assignment of his or her study subject number. Maintenance weekly dosing is initially half of the adjusted dose (3 x 20 pg/kg IV body weight, which is later modified accordingly per patient for epoetin beta 16 and 75-300 pg/kg IV with adjusted doses 50 pg/kg x 3 IV for epoetinum alfa17). A 200-IU: 1-pg ratio 18 was used initially for switching patients from rHuEPO to darbepoetin alfa. The Q2W dose of darbepoetin alfa was calculated by adding 2 total weekly doses of rHuEPO and then converting to the corresponding darbe- poetin alfa dose. The calculated darbepoetin alfa dose was then rounded to the nearest of the available unit doses (10, 15, 20, 30, 40 , 50, 60, 80, 100, 130, and 150 pg). Darbepoetin alfa was the only investigational agent in this study, and it was provided free of charge to the study patients. It was provided as a clear, colorless, human serum albumin (HSA)-free, sterile protein solution in prefilled syringes. The first dose of study drug was administered to the patient at the hemodialysis unit or the peritoneal dialysis clinic within 7 days of assignment of study subject number. Darbepoetin alfa was administered by the same route (IV or SC) as previous rHuEPO therapy. IV injections were administered through the venous dialysis line during the dialysis session, according to the dosing schedule. SC injections were administered at home by the patient or a nurse after proper training by the investigators.
Treatment Assignment and Study Drug Administration

Study Visits
Patients were to return to the clinic at weekly intervals during the dose-titration and evaluation periods for Hb concentration measurement. Iron status (serum ferritin concentration and transferrin saturation) was also assessed, at weeks 0 (baseline), 8, 16, and 24. A follow-up examination and assessments were performed at week 25 (study end). Blood samples were drawn by a nurse. Samples were processed on the same day based on current practice guidelines. Patients were instructed to visit the clinic for their assessments on the same day of the week as the first administration of study drug. This schedule was especially important for patients receiving hemodialysis, for whom assessments needed to be performed at consistent times in relation to their dialysis sessions.
Efficacy Assessment
The primary end point of the study was the change in Hb concentration between screening and baseline. Patients were divided into 2 groups by route of administration to analyze whether the route of administration affected dose requirements. The extent of unit dosing and frequency of administration (ie, the number of dose adjustments and dosing frequency changes) were also evaluated.
Dose Adjustments
During the 20-week dose-titration period, clinicians were to adjust the darbepoetin alfa dose each time 2 consecutive Hb measurements were outside the target range of 10 to 13 g/dL. Hb concentrations were determined every other week, with concentrations outside the target range confirmed on repeat measurement within 7 days. If a patient had 2 consecutive Hb measurements above the target range (>13 g/dL), the darbepoetin alfa dose was decreased to the next-lower unit dose. Conversely, if the Hb concentration was below the target range (<10 g/dL) on 2 consecutive determinations, the dose was increased to the next-higher unit dose. Dose adjustments were to occur only in 1-step increments on the list of allowable unit doses.
If a patient had 2 consecutive Hb concentrations above the target Hb range after the darbepoetin alfa dose had been decreased to 10 pg/wk, then the dosing frequency was reduced. Conversely, if a patient had 2 consecutive Hb concentrations below the target Hb range after the dose had been increased to 150 pg/wk, then the dosing frequency was increased. Dosing frequency was adjusted incrementally as follows: Q2W o QW o BIW ~ TIW.
If the Hb concentration was >14 g/dL, it was immediately confirmed with a repeat measurement and darbepoetin alfa administration was discontinued until the Hb concentration decreased to within the target range. Darbepoetin alfa was then reinitiated at the next-lower unit dose.
In patients who received ___1 RBC transfusion during the study, the doseadjustment guidelines were not applicable. In this situation, doses were adjusted at the discretion of the treating physician, although the protocol did recommend that they be increased only if a patient's Hb concentration was <10 g/dL after receiving an RBC transfusion.
If anemia was nonresponsive to darbepoetin alfa therapy, patients were assessed for common causes of poor erythropoiesis, including iron and/or vitamin deficiencies, hemorrhage, infection, and secondary hyperparathyroidism. If these potential causes of a poor response to therapy were excluded, the investigator could request that a test for darbepoetin alfa seroreactivity be performed (all tests were to be performed by the study sponsor).
Tolerability Assessment
Tolerability was assessed using spontaneous reports of adverse events and the results of clinical laboratory tests (hematology, vital sign measurement, iron status, and biochemistry). The nature, frequency, severity, and relation to treatment of all adverse events were evaluated.
Statistical Analysis
An intent-to-treat (ITT) analysis, which included all patients assigned a study subject number, was performed for the primary analysis of efficacy. If a patient discontinued the study prior to the evaluation period, the last available value was carried forward. Tolerability analyses were based on all patients who received ~1 dose of darbepoetin alfa (per-protocol [PP] population). Statistical analyses were performed using SAS version 8.2 (SAS Institute, Inc., Cary, North Carolina). The analysis plan included the following: (1) the generation of descriptive statistics, including means (SD or SE); medians; ranges; interquartile ranges; and, where appropriate, 95% CIs; and (2) analytical statistics, including analysis of variance performed in the ITT population. P < 0.05 was considered statistically significant.
RESULTS
Study Population
A total of 173 patients (98 men, 75 women) were recruited into the study (ITT population; IV, n --146; SC, n --27) and 172 received _~1 dose of the study drug (PP population; IV, n = 145; SC, n = 27). One patient withdrew consent prior to receiving darbepoetin alfa. The demographic and clinical characteristics of the study patients are shown in Table I . All participants were white, ethnic Greeks, although race was not an eligibility or recruitment criterion. The mean age of patients enrolled in the study was 57.6 years; 111 patients (64%) were aged <65 years, and of the remaining 36%, 17 patients (10%) were aged ~75 years.
One hundred forty-six patients (84%) were receiving hemodialysis and rHuEPO IV before the study. Overall, the most prevalent primary cause of renal failure was unknown (50 patients [29%]), followed by glomerulonephritis (45 [26%]), hypertension (21 [12%]), and diabetes mellitus (17 [10%] ). The mean (SD) baseline Hb concentration was 11.45 (0.70) g/dL in the IV group and 11.28 (0.85) g/dL in the SC group. Although these 2 concentrations were similar, a numerically higher percentage of patients in the SC group had a depressed Hb concentration (<11 g/dL) (10 patients [37%]) compared with the IV group (36 patients [25%]) (Table I) .
At baseline, 70% of patients were receiving epoetin alfa and 30% were receiving epoetin beta; 95% were receiving rHuEPO via prefilled syringes (mean dosage, 6405 U/wk). One hundred seven patients (62%) were receiving rHuEPO TIW, irrespective of administration route; 40 (23%), BIW; and 24 (14%), QW. After these patients were switched to darbepoetin alfa, 145 (84%) received therapy QW and 28 (16%) received therapy Q2W. Table II presents 
Effectiveness
During the dose-titration period, the original dosing schedule was unchanged or was adjusted only once in the majority of patients (125 [72%]). In 22 patients (13%), the dose was titrated twice; in the remaining 26 (15%), 3 or 4 adjustments were required to reach the optimal dose. However, when the dose was adjusted properly, 90% of the patients continued receiving darbepoetin alfa without requiring further dose modifications. The remaining 10% required further dose modifications due to idiosyncrasies.
During the evaluation period, 5 of 28 patients (18%) assigned to receive darbepoetin alfa Q2W had the dosing frequency increased to QW. Of the 145 patients assigned to receive darbepoetin alfa QW, 1 (1%) had the dosing frequency increased to BIW, and 1 (1%) to Q2W.
During the evaluation period, 143 patients (83%) had Hb concentrations within the recommended range, whereas 12 patients (7%) had Hb concentrations outside the target range (lib <10 g/dL, 2 patients [1%]; Hb >13 g/dL, 10 patients [6%]). In the IV group, 118 of 146 patients (81%) had Hb concentrations _11 g/dL during this period versus 110 patients (75%) at baseline. Of the patients in the SC group, 21 of 27 patients (78%) had Hb concentrations >11 g/dL during the evaluation period versus 17 patients (63%) at baseline. A significant difference in the mean darbepoetin alfa starting dose was noted between the 2 routes of administration at baseline (P = 0.03), but no significant difference was observed during the evaluation period. Only 7 patients (4%) received RBC transfusions during the dose-titration/evaluation periods. The mean unadjusted increases in Hb concentration were 0.28 g/dL in the IV group and 0.17 g/dL in the SC group. For patients receiving darbepoetin alfa QW (IV, 131 patients; SC, 17 patients)--and after baseline Hb concentration, frequency, route, and dose of rHuEPO at entry and mode of dialysis were controlled--the mean (SE) adjusted Hb increases versus baseline were 0.94 (0.32) g/dL in the IV group (P = 0.004) and 0.38 (0.30) g/dL in the SC group (P = NS) (Table III and Figure 2 ). For those receiving darbepoetin alfa Q2W (IV, 15 patients; SC, 10 patients)--and after the above variables were controlled--the mean (SE) adjusted increases in Hb concentration were 0.08 (0.53) g/dL and 0.48 (0.35) g/dL in the IV and SC groups, respectively; the differences were not statistically significant (Table Ill) . Differences in dose requirements between baseline and the evaluation period are shown in Table IV and Figure 3 .
Tolerability
No antibody formation was observed in any of the study participants (ie, no tests for seroreactivity to darbepoetin alfa were requested by the investigators). Five deaths (3%) were reported during the study period. These deaths appeared to be the result of comorbid conditions consistent with this patient 
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._= 0  I  I  I  I  I  ]  I  I  I  I  I  I  I  I   -2 population and were not considered by the attending physicians to be related to the study drug. Three of the 5 deaths were cardiovascular in nature (cardiogenic shock, cardiac arrest, and supraventricular tachycardia). One death was attributed to sepsis, and 1 death was due to cachexia. No deaths were reported during the evaluation or follow-up periods. Thirty-three patients (19%) reported adverse events, as follows: hypertension (8 patients [5%]); vascular access thrombosis (4 [2%]); access hemorrhage and headache (3 [2%] each); fever, malaise, atrial fibrillation, angina pectoris, respiratory tract infection, fracture, and cholelithiasis (2 [1%] each); and inflammation (1 [1%] ).
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Overall, the incidence of treatment-related adverse events was 3% (6 patients). The reported treatment-related adverse events were hypertension (4 patients [2%]), headache and insomnia (1 [1%]), and dry mouth (1 [1%]) ( Table V) . None of the adverse events were considered severe. Hypertension led to study withdrawal in 1 case (1%). Tolerability analyses by age, sex, dialysis mode, baseline Hb concentration, and a subanalysis of administration route revealed no notable differences among these subgroups. There were no significant changes in laboratory data. Adequate iron stores were maintained according to European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure 13 and the National Kidney Foundation Dialysis Outcomes Quality Initiative guidelines, 19 as mean transferrin saturation was >20% throughout the study and median serum ferritin concentration was >100 pg/L for all 24 weeks. Median serum ferritin concentration was 382 pg/L at baseline, 343 pg/L at week 16, 349 pg/L at week 24, and 341 pg/L at the end of the study. 
DISCUSSION
This study found that in patients with ESRD receiving dialysis, Hb concentrations were effectively maintained within the recommended target range after switching from rHuEPO to a less-frequent dosing regimen of HSA-free darbepoetin alfa without an increase in dose. At baseline, the mean Hb concentration of the study patients was _>11 g/dL in both the IV and SC groups. However, the proportions of patients who achieved target Hb concentrations were 75% in the IV group and 63% in the SC group. Although these results exceed the European averages, 2°,21 they lag behind current clinical recommendations. The target of the European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure 13 is for 85% of patients to achieve an Hb concentration of >11 g/dL in the maintenance phase of erythropoietic treatment. Thus, an improvement in the management of anemia due to ESRD would be beneficial for patients undergoing dialysis.
In the present study, mean Hb concentrations were maintained at _>11 g/dL throughout the treatment and evaluation period, regardless of route or frequency of administration of darbepoetin alfa. The percentages of patients with Hb levels _>11 g/dL were increased from 63% to 78% in patients receiving darbepoetin alfa SC and from 75% to 81% in those receiving darbepoetin alfa IV.
Similar to the findings of Locatelli et al, 12 the data in the present study suggest that IV administration results in greater increases in Hb concentration than SC administration. This may be attributed partially to the lower baseline Hb concentrations in patients receiving rHuEPO SC. However, the dosage IV/SC ratio that was found also suggests that there is no difference in dose requirements for the different routes of administration. According to Locatelli et al, 12 the pharmacokinetic characteristics of darbepoetin alfa compared with rHuEPO (eg, longer tl/2, which results in the ability to be administered less frequently) may explain why there was no difference in dose requirements between the IV and SC routes of administration. This finding offers dosing flexibility to physicians prescribing darbepoetin alfa. Due to its increased carbohydrate content, the level of darbepoetin alfa in the circulation remains above the minimum stimulatory concentration for erythropoiesis for longer than the equivalent molar dose of rHuEPO, allowing darbepoetin alfa to be administered less frequently to achieve the same biological response.
Overall, HSA-free darbepoetin alfa was well tolerated in this study. The tolerability data were consistent with that expected for patients with ESRD who undergo dialysis. The tolerability data are supported by previous reports suggesting that darbepoetin alfa is well tolerated, 22 with a safety profile similar to that of rHuEPO. 23 In the present study, 19% of patients reported adverse events. Three percent of patients reported treatment-related adverse events, the majority of which were due to the development of hypertension. The incidence of hypertension related to darbepoetin treatment reported in the literature ranges from 2% 13 to 30%. 24 Furthermore, 1 patient reported headache and insomnia and another patient reported dry mouth.
In the present study, Hb concentrations were maintained within a recommended target range with darbepoetin alfa at a less-frequent dosing schedule compared with rHuEPO. The ability to dose patients less frequently offers the advantage of convenience. A proper pharmacoeconomic evaluation is needed to estimate the potential cost-effectiveness of darbepoetin alfa in comparison with standard rHuEPO treatment.
One limitation was that the eligibility criteria limit the ability to extrapolate the results of this study to the general population. Moreover, the study had further limitations, such as being open label and uncontrolled, with a small number of patients in the SC group.
CONCLUSIONS
In this study in patients with ESRD receiving dialysis who were switched from rHuEPO to darbepoetin alfa administered IV or SC, darbepoetin alfa effectively maintained Hb concentrations within the target range of 10 to 13 g/dL without the need for a dose increase, even at a reduced dosing frequency (Q2W). Overall, darbepoetin alfa was well tolerated.
